[et_pb_section fb_built=”1″ _builder_version=”4.0.6″ custom_padding=”||2px|||”][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”1″ _builder_version=”4.0.4″ background_color=”#00a1e4″ width=”100%” max_width=”1920px” min_height=”462px” custom_margin=”-56px|auto||auto|false|false” custom_padding=”||0px|||”][et_pb_column type=”1_3″ _builder_version=”4.0.4″][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.0.6″][et_pb_text _builder_version=”4.0.6″ header_2_font=”|300|||||||” header_2_text_color=”#ffffff” header_2_font_size=”80px” header_2_letter_spacing=”5px” custom_margin=”78px||||false|false”]<\/p>\n
[\/et_pb_text][et_pb_divider color=”#005496″ _builder_version=”4.0.4″ width=”53%” module_alignment=”center” custom_margin=”36px||||false|false”][\/et_pb_divider][et_pb_text _builder_version=”4.0.6″ header_font=”|||on|||||” header_4_font=”|||on|||||” header_4_text_color=”#FFFFFF” header_4_font_size=”30px” hover_enabled=”0″]<\/p>\n
[\/et_pb_text][et_pb_divider color=”#005496″ _builder_version=”4.0.4″ width=”53%” module_alignment=”center” custom_margin=”16px||||false|false”][\/et_pb_divider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.0.4″][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.0.6″ custom_padding=”0px|||||”][et_pb_row _builder_version=”4.0.6″ custom_padding=”||0px|||”][et_pb_column type=”4_4″ _builder_version=”4.0.6″][et_pb_text _builder_version=”4.0.6″ header_2_text_color=”#005496″ custom_margin=”||7px|||” custom_padding=”||0px|||” hover_enabled=”0″]<\/p>\n
MOUNT LAUREL, N.J. \u2013 October 30, 2019\u00a0\u2013 Impulse Dynamics<\/a>, developer of the implantable Optimizer\u00a0Smart System for delivering CCM\u00d4 (Cardiac Contractility Modulation) therapy, announced today that it has received FDA approval of a PMA supplement for its next generation, two-lead Optimizer Smart System for the treatment of heart failure.<\/p>\n The Optimizer Smart System offers a new therapy for heart failure patients with reduced ejection fraction who are still suffering from the debilitating effects of the disease despite guideline-directed medical therapy. New algorithms in the two-lead version of Optimizer Smart deliver therapy just as the previous device did, but no longer require inputs from an atrial lead. Recent evidence from the FIX-HF-5C2 clinical study indicates that patients who received the two-lead system experienced better outcomes, including improved peak VO2 <\/sub>(a common measure of exercise tolerance), and fewer device-related complications.1<\/sup>\u00a0<\/p>\n \u201cI\u2019ve had the opportunity to provide CCM therapy using both the two-lead and three-lead Optimizer Smart systems. In my opinion, this approval represents an important advancement that will make this breakthrough therapy even more accessible to patients,\u201d said cardiac electrophysiologist Dr. Thomas Mattioni, Scottsdale, Ariz. \u201cPatients with Class III heart failure who remain unresponsive to conventional therapy have few options, and CCM is an important addition to our armamentarium in this respect. I have several patients who have had a remarkable response to CCM, and think it is an option providers should be able to consider for patients who are appropriately indicated.\u201d<\/p>\n CCM is a unique electrical therapy delivered during the heart\u2019s absolute refractory period, which is just after the heart muscle contracts. In contrast to a pacemaker or defibrillator, CCM works by modulating the strength of the heart muscle contraction rather than the rhythm. The Optimizer Smart System is the first and only CCM device approved by the FDA to improve 6-minute hall walk distance, quality of life and functional status of NYHA Class III heart failure patients who remain symptomatic despite guideline directed medical therapy, who are in normal sinus rhythm, are not indicated for CRT, and have a left ventricular ejection fraction (LVEF) ranging from 25 to 45 percent. Only 30 percent of moderate to severe chronic heart failure patients are candidates for CRT, which historically has left 70 percent of patients with few options to help them manage their disease.<\/p>\n \u201cThe benefits of Cardiac Contractility Modulation have now been proven with evidence-based medicine and in my clinical practice,\u201d said Dr. Ben D\u2019Souza, Assistant Clinical Professor at Penn Medicine, Philadelphia. \u201cPatients already receive significant benefit from this therapy in its present form and removing the need for an atrial lead is an important advancement for both patients and providers.\u201d<\/p>\n Designed to address a significant unmet medical need in heart failure, the Optimizer Smart System received Breakthrough Device designation from the FDA in 2015. It was the first Breakthrough Device to go before the Circulatory System Devices Panel of the FDA\u2019s Medical Devices Advisory Committee, on Dec. 4, 2018, receiving a unanimous recommendation for approval based on their assessment of benefit versus risk. Optimizer then went on to receive FDA approval on March 21, 2019.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.0.6″ background_color=”#005496″ custom_padding=”37px|36px|37px|36px|true|true”][et_pb_column type=”1_3″ _builder_version=”4.0.6″][et_pb_text _builder_version=”4.0.6″ background_layout=”dark”]<\/p>\n About the Optimizer and CCM Therapy <\/p>\n [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.0.6″][et_pb_text _builder_version=”4.0.6″ background_layout=”dark”]<\/p>\n About Impulse Dynamics [\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.0.6″][et_pb_text _builder_version=”4.0.6″ background_layout=”dark”]<\/p>\n Impulse Dynamics (USA), Inc.<\/strong> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.0.4″ background_color=”#005496″ custom_margin=”-8px|||||” custom_padding=”0px||0px||true” global_module=”79″ saved_tabs=”all” collapsed=”off”][et_pb_row use_custom_gutter=”on” gutter_width=”2″ custom_padding_last_edited=”on|tablet” _builder_version=”4.0.6″ max_width=”1400px” custom_padding=”15px||5px||false” custom_padding_tablet=”0px||0px||false|false” custom_padding_phone=””][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_signup mailchimp_list=”Impulse Dynamics|b1aca3c5b7″ ip_address=”off” first_name_field=”off” last_name_field=”off” title=”IMPULSE DYNAMICS NEWSLETTER” button_text=”SIGN UP” description=”<\/p>\n Sign up to receive our monthly newsletter <\/p>\n ” footer_content=”<\/p>\n
<\/strong>CCM is the brand name for Cardiac Contractility Modulation, the non-excitatory electrical pulses delivered by the implantable Optimizer device during the absolute refractory period of the heart\u2019s cardiac cycle to improve systolic contraction of the heart. The Optimizer System has been implanted in over 4,000 patients and is currently available in the US, Europe, China, Brazil, India, and more than 40 other countries around the world. Impulse Dynamics has completed numerous clinical studies, including several randomized controlled trials, and the results have been published in over 80 articles appearing in leading medical journals.<\/p>\n
<\/strong>Impulse Dynamics is a medical device company dedicated to transforming the treatment of chronic heart failure. With global headquarters in Mount Laurel, N.J., the company has additional offices in; Stuttgart, Germany, Orangeburg, N.Y. and Curacao For more information please visit\u00a0<\/span>www.impulse-dynamics.com<\/a>.<\/p>\n
523 Fellowship Road, Suite 203
Mt. Laurel, NJ 08054<\/p>\n